High-Dose therapy plus stem cell transplant shows promise for AML patients

NCT ID NCT00534469

Completed Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell production. After transplant, they also received aldesleukin (a protein that boosts the immune system) to help prevent relapse. The study aimed to see how well this approach worked and what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: busulfan, etoposide, total-body irradiation, aldesleukin, filgrastim, cytarabine, idarubicin
What this could lead to: If successful, this approach could improve disease-free survival for AML patients in first remission, potentially reducing relapse risk.
What could go wrong: This is a completed phase 2 trial with only 60 participants, so results may not apply broadly. High-dose chemo and radiation carry significant side effects, and the transplant may not prevent relapse in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute basophilic leukemia acute erythroid leukemia acute megakaryoblastic leukemia acute monocytic leukemia acute myeloid leukemia Congenital Abnormalities leukemia Leukemia, Eosinophilic, Acute Leukemia, Myelomonocytic, Acute

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.